How cloud technologies continue to enable innovation in the pharmaceutical industry

Cloud Computing News | October 23, 2019

The pharmaceutical world is in the midst of a sea change. As new deadlines approach for compliance with the Drug Supply Chain Security Act (DSCSA), pharmaceutical companies are racing — and struggling — to comply. The provisions’ end goal — creating an electronic database to identify and trace the distribution of prescription drugs throughout the U.S. and ensuring proper licensing — is clearly an important one for public safety. But that doesn’t mean it’s an easy transition. Meanwhile, companies still are going about their regular business of developing life-changing pharmacological solutions. To be successful, organisations must maintain a delicate balancing act, and aren’t able to fully direct their attention to any one area. Fortunately, modern cloud technology, including enterprise resource planning, stands to aid pharmaceutical executives with these challenges. Not only do cloud technologies help companies update their reporting and accounting processes to meet modern standards, they open up new internal efficiencies that allow for unprecedented innovation. Here are a few ways cloud solutions will benefit modern pharmaceutical companies.

Spotlight

Sustainalytics is an independent ESG and corporate governance research, ratings and analysis firm supporting investors around the world with the development and implementation of responsible investment strategies. With 14 offices globally, Sustainalytics partners with institutional investors who integrate environmental, social and governance information and assessments into their investment processes. Today, the firm has more than 250 staff members, including 170 analysts with varied multidisciplinary expertise of more than 40 sectors. Through the IRRI survey, investors selected Sustainalytics as the best independent responsible investment research firm for three consecutive years, 2012 through 2014 and in 2015, Sustainalytics was named among the top three firms for both ESG and Corporate Governance research. For more information, visit www.sustainalytics.com.

Spotlight

Sustainalytics is an independent ESG and corporate governance research, ratings and analysis firm supporting investors around the world with the development and implementation of responsible investment strategies. With 14 offices globally, Sustainalytics partners with institutional investors who integrate environmental, social and governance information and assessments into their investment processes. Today, the firm has more than 250 staff members, including 170 analysts with varied multidisciplinary expertise of more than 40 sectors. Through the IRRI survey, investors selected Sustainalytics as the best independent responsible investment research firm for three consecutive years, 2012 through 2014 and in 2015, Sustainalytics was named among the top three firms for both ESG and Corporate Governance research. For more information, visit www.sustainalytics.com.

Related News

BUSINESS INSIGHTS

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

Neurimmune | January 17, 2022

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ technology platform, a unique antibody drug creation approach. In November 2017, Ono and Neurimmune signed a first drug discovery collaboration agreement to identify and develop human antibodies using the RTM™ technology platform. In the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from the collaboration. Ono will pay to Neurimmune an upfront payment, research fees, success-based milestones on the research and development progress, as well as royalties on product sales. "We are excited to expand our long-term trusted partnership with Ono, a global pioneer of innovative medicines. The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology." Jan Grimm, CSO of Neurimmune "We extremely appreciate Neurimmune's RTM™ technology platform as an excellent antibody creation technology through our drug discovery projects." said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. "Through this new collaboration, we will expand our central nervous system disease portfolio and work to deliver innovative medicines to patients with neurodegenerative diseases." About Neurimmune Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer's disease, and licensed it to Biogen. With its RTM™ technology, Neurimmune also discovered the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.

Read More

PHARMA TECH

Tetrate-Named-2021-Cool-Vendor-in-Cloud-Computing-by-Gartner

Omnicell | November 11, 2021

Omnicell, Inc. a leading provider of medication management solutions and adherence tools for health systems and pharmacies, and Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Managing controlled substances is a significant challenge for hospitals and clinics. According to a recent study, more than 148 million doses of medicine were lost in 2019, compromising both patient and workforce safety.1 Omnicell’s Controlled Substance Dispenser (CSD) is a leading high-volume, automated single dose dispensing solution designed to help pharmacies better manage controlled substances, reduce diversion, and save nursing time. By providing only one dose at a time, the CSD is designed to eliminate the need for countbacks and decrease the time required to resolve discrepancies to provide nurses more time for direct patient care and discourage diversion.2 Through its relationship with Fresenius Kabi, Omnicell has designed new cassettes for its CSD specifically for Fresenius Kabi Simplist® MicroVault® prefilled syringes that will provide customers more flexibility with their medication supply chain and enhanced controlled substance management initiatives. The new Fresenius Kabi cassettes for the Omnicell CSD are available now. Fresenius Kabi Simplist® MicroVault® prefilled syringes are used by hospitals in the United States in an effort to help reduce the amount of time nurses spend preparing doses and documenting waste. The error rate is four times lower using these prefilled syringes compared with traditional medication administration practices.3 The new cassettes for the Omnicell CSD will accommodate MicroVault® packaging for a variety of low-dose narcotic medications including morphine, hydromorphone, and fentanyl. The syringes are manufacturer-prepared in the United States, with a 24-month shelf life, and are single-unit doses, supporting best practices for medication administration. “Omnicell is committed to addressing the biggest challenges in pharmacy care delivery through technology Through innovative collaborations with healthcare leaders like Fresenius Kabi, we’re delivering the solutions designed to help our customers manage controlled substances, reduce diversion, optimize inventory, and enhance clinical workflows to support optimal care and patient safety.” Nish Parekh, Omnicell’s Vice President of Product Management for Point of Care Solutions “Fresenius Kabi is committed to medication safety and the responsible use of controlled substances,” said Angie Lindsey, Vice President of Marketing for Fresenius Kabi USA. “The combination of Omnicell’s Controlled Substance Dispenser automation workflow with Fresenius Kabi Simplist® MicroVault® prefilled syringes will offer healthcare providers advanced tools and technology to achieve these aims.” The Fresenius Kabi-Omnicell relationship and offering is an important step toward the vision of the Autonomous Pharmacy, a roadmap to develop a zero-error, fully automated medication management infrastructure. Through Omnicell’s industry leading medication management portfolio of hardware, software, and technology-enabled services delivered through the cloud, many health systems and retail pharmacies are realizing how connected technology and intelligence can help solve some of the most pressing challenges in medication management. About Fresenius Kabi Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help treat critical and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi. About Omnicell Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 60,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. Forward-Looking Statements Certain statements contained in this press release relate to future plans and objectives regarding Omnicell’s products and services. These statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, those described in the Risk Factors section of Omnicell’s most recent annual report on Form 10-K and quarterly report on Form 10-Q and in the Company’s other filings with the U.S. Securities and Exchange Commission. Forward-looking statements should be considered in light of these risks and uncertainties. Investors are cautioned not to place undue reliance on forward-looking statements. All forward looking statements contained in this press release speak only as of the date of this press release. Omnicell undertakes no obligation to update such statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

Read More

BUSINESS INSIGHTS

With Veeva eConsent, Celerion is changing the consent experience for clinics and patients

Veeva Systems | October 07, 2021

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we could spend with attendees. So we needed new and digital ways to advance our studies while meeting regulatory requirements for proper consent, - Staci McDonald , Executive Director, Scientific Clinical Operations at Celerion . An easy-to-use solution that can keep pace with our fast-paced environment and improves the participants' understanding of the study processes. The implementation of the solution went smoothly, and the feedback from the study teams, on-site staff and participants was positive. " Celerion, a leading global provider of early clinical research services, uses Veeva SiteVault to digitally create, manage and distribute informed consent (ICF). Patients can then securely access the eConsent document and complete the consent process via a mobile device. This simplifies the comparison of documents and reduces the administrative effort for the locations. Thanks to a seamless flow of information, Celerion has a complete overview of the status of consent and can thus improve study compliance and monitoring. Celerion is driving industry collaboration by leveraging digital solutions that enable patient-centric, paperless clinical trials, Veeva eConsent improves the process of informed consent for everyone Stakeholders by providing an intuitive and digital experience for patients and easy collaboration with locations and IRBs for sponsors. - Tim Davis , vice president, MyVeeva for Patients at Veeva Systems. About Veeva Systems Veeva is the world's leading provider of cloud software for the life science industry. Veeva is committed to innovation, product quality and customer success, serving more than 1,000 customers from the world's largest pharmaceutical companies to emerging biotech companies. As a not-for-profit, Veeva is committed to aligning the interests of all stakeholders, including customers, employees, shareholders and the industries it serves.

Read More